Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
boston blog main
boston top stories
life sciences
national blog main
national top stories
3
×
akcea therapeutics
alnylam pharmaceuticals
biotech
drugs
fda
hereditary transthyretin amyloidosis
inotersen
new york blog main
new york top stories
patisiran
san diego blog main
san diego top stories
tafamidis
barry greene
biopharma
boston university
clinical trials
dan ollendorf
deals
duchenne
europe blog main
europe top stories
european medicines agency
harvard pilgrim health care
institute for clinical and economic review
john berk
licensing
m&a
mary o'donnell
muscular dystrophy
onpattro
pfizer
regeneron pharmaceuticals
rna interference
What
fda
medicine
3
×
rna
3
×
alnylam
gene
historic
uses
ago
approval
approve
approves
awaits
betting
billion
biological
biopharma
cells
crossed
deal
decades
decision
discovered
drug
duchenne
ema
employ
europe
fingers
follows
friday
harmful
hits
interference
make
method
mute
patients
protein
puts
recently
Language
unset
Current search:
rna
×
medicine
×
" national top stories "
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision